Published in J Gastroenterol on February 24, 2008
Clinical effectiveness of selective granulocyte, monocyte adsorptive apheresis with the Adacolumn device in ulcerative colitis. Dig Dis Sci (2009) 1.57
The GRADE approach for assessing new technologies as applied to apheresis devices in ulcerative colitis. Implement Sci (2010) 0.94
Granulocyte-monocyte apheresis for the treatment of ulcerative colitis--is this the end of the road? Nat Clin Pract Gastroenterol Hepatol (2008) 0.86
Daily granulocyte and monocyte adsorptive apheresis in patients with active ulcerative colitis: a prospective safety and feasibility study. J Gastroenterol (2011) 0.82
The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. J Gastroenterol (2010) 0.81
Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2. World J Gastroenterol (2015) 0.77
Current topics on therapeutic apheresis. J Artif Organs (2010) 0.76
Leukocyte apheresis in the management of ulcerative colitis. Saudi J Gastroenterol (2009) 0.75
Inflammatory bowel disease. N Engl J Med (2002) 21.17
VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS. Br Med J (1964) 7.02
Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med (1994) 6.05
A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology (1989) 4.27
Incidence rates of ulcerative colitis and Crohn's disease in fifteen areas of the United States. Gastroenterology (1981) 1.99
Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci (2004) 1.92
Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol (2005) 1.70
Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study. Int J Colorectal Dis (2006) 1.53
The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis (2000) 1.53
Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher (2001) 1.52
Novel pathophysiological concepts of inflammatory bowel disease. J Gastroenterol (2006) 1.46
Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis (2004) 1.29
Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol (2003) 1.18
Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther (2004) 1.18
IL-5 and TNF-alpha participate in recruitment of eosinophils to intestinal mucosa in ulcerative colitis. Dig Dis Sci (2001) 1.12
Adsorptive granulocyte and monocyte apheresis for refractory Crohn's disease: an open multicenter prospective study. J Gastroenterol (2004) 1.12
Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci (2002) 1.09
Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis. Am J Gastroenterol (2000) 0.90
Granulocyte and monocyte apheresis suppresses symptoms of rheumatoid arthritis: a pilot study. Rheumatol Int (1998) 0.88
Anti-inflammatory effect of granulocyte and monocyte adsorption apheresis in a rabbit model of immune arthritis. Inflammation (2002) 0.81
The current status of T-lymphocyte apheresis (TLA) treatment of Crohn's disease. J Clin Gastroenterol (1989) 0.80
Is there a role for apheresis in gastrointestinal disorders? Nat Clin Pract Gastroenterol Hepatol (2005) 0.78
Intestinal crypt homeostasis results from neutral competition between symmetrically dividing Lgr5 stem cells. Cell (2010) 12.23
Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol (2012) 7.39
Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell (2010) 7.25
In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. Nature (2013) 4.94
PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat Genet (2007) 4.09
Current view: intestinal stem cells and signaling. Gastroenterology (2008) 3.46
Isolation and in vitro expansion of human colonic stem cells. Nat Med (2011) 3.20
Functional engraftment of colon epithelium expanded in vitro from a single adult Lgr5⁺ stem cell. Nat Med (2012) 3.17
Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J Clin Invest (2008) 3.00
Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis (2011) 2.95
A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology (2004) 2.75
Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology (2002) 2.71
Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis. EMBO J (2013) 2.24
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
Damaged epithelia regenerated by bone marrow-derived cells in the human gastrointestinal tract. Nat Med (2002) 2.18
Effects of family history on inflammatory bowel disease characteristics in Japanese patients. J Gastroenterol (2012) 2.17
Th1/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn's disease. Gastroenterology (2009) 2.15
Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease. Hepatology (2008) 2.05
Controlled gene expression in primary Lgr5 organoid cultures. Nat Methods (2011) 1.98
Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease. Inflamm Bowel Dis (2008) 1.90
Ameliorating effects of compounds derived from Salvia miltiorrhiza root extract on microcirculatory disturbance and target organ injury by ischemia and reperfusion. Pharmacol Ther (2007) 1.87
Abnormally differentiated subsets of intestinal macrophage play a key role in Th1-dominant chronic colitis through excess production of IL-12 and IL-23 in response to bacteria. J Immunol (2005) 1.82
Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110δ. Gastroenterology (2010) 1.80
Blatchford scoring system is a useful scoring system for detecting patients with upper gastrointestinal bleeding who do not need endoscopic intervention. J Gastroenterol Hepatol (2007) 1.80
Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. Inflamm Bowel Dis (2010) 1.78
Imbalance of NKp44(+)NKp46(-) and NKp44(-)NKp46(+) natural killer cells in the intestinal mucosa of patients with Crohn's disease. Gastroenterology (2010) 1.71
Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol (2003) 1.70
Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol (2005) 1.70
Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int J Med Microbiol (2007) 1.65
Inhibition of neutrophil elastase prevents the development of murine dextran sulfate sodium-induced colitis. J Gastroenterol (2006) 1.62
Regulatory T cells suppress development of colitis, blocking differentiation of T-helper 17 into alternative T-helper 1 cells. Gastroenterology (2011) 1.61
Helicobacter pylori: present status and future prospects in Japan. J Gastroenterol (2007) 1.57
Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. Am J Gastroenterol (2006) 1.56
The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol (2005) 1.55
A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology (2008) 1.53
Dietary fat attenuates the benefits of an elemental diet in active Crohn's disease: a randomized, controlled trial. Eur J Gastroenterol Hepatol (2003) 1.51
Expanded B cell population blocks regulatory T cells and exacerbates ileitis in a murine model of Crohn disease. J Clin Invest (2004) 1.50
Reactive oxygen species-induced autophagic degradation of Helicobacter pylori CagA is specifically suppressed in cancer stem-like cells. Cell Host Microbe (2012) 1.49
The use of infliximab in the prevention of postsurgical recurrence in polysurgery Crohn's disease patients: a pilot open-labeled prospective study. Int J Colorectal Dis (2012) 1.48
Novel pathophysiological concepts of inflammatory bowel disease. J Gastroenterol (2006) 1.46
Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol (2009) 1.45
Gatifloxacin resistance and mutations in gyra after unsuccessful Helicobacter pylori eradication in Japan. Antimicrob Agents Chemother (2006) 1.44
Contribution of efflux pumps to clarithromycin resistance in Helicobacter pylori. J Gastroenterol Hepatol (2010) 1.43
Biliary findings assist in predicting enlargement of intraductal papillary mucinous neoplasms of the pancreas. Clin Gastroenterol Hepatol (2012) 1.43
Effects of Aging on Visceral and Subcutaneous Fat Areas and on Homeostasis Model Assessment of Insulin Resistance and Insulin Secretion Capacity in a Comprehensive Health Checkup. J Atheroscler Thromb (2015) 1.41
Development of consensus statements for the diagnosis and management of intestinal Behçet's disease using a modified Delphi approach. J Gastroenterol (2007) 1.40
Side population of pancreatic cancer cells predominates in TGF-beta-mediated epithelial to mesenchymal transition and invasion. Int J Cancer (2009) 1.40
Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan. J Gastroenterol (2012) 1.40
A novel apoptosis-inducing monoclonal antibody (anti-LHK) against a cell surface antigen on colon cancer cells. J Gastroenterol (2005) 1.39
A case of beef tapeworm (Taenia saginata) infection observed by using video capsule endoscopy and radiography (with videos). Gastrointest Endosc (2011) 1.39
Prevalence of ulcerative colitis and Crohn's disease in Japan. J Gastroenterol (2009) 1.39
Helicobacter pylori eradication therapy. Future Microbiol (2010) 1.38
Abnormal mucosal immune response to altered bacterial flora following restorative proctocolectomy in patients with ulcerative colitis: serologic measures, immunogenetics, and clinical correlations. Clin Immunol (2008) 1.38
Mucosal T cells expressing high levels of IL-7 receptor are potential targets for treatment of chronic colitis. J Immunol (2003) 1.37
Helicobacter pylori and gastric cancer. Gastric Cancer (2009) 1.34
Monocyte chemoattractant protein-1 contributes to gut homeostasis and intestinal inflammation by composition of IL-10-producing regulatory macrophage subset. J Immunol (2010) 1.31
An anti-inflammatory role for carbon monoxide and heme oxygenase-1 in chronic Th2-mediated murine colitis. J Immunol (2011) 1.31
Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. J Gastroenterol (2002) 1.30
Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis (2004) 1.29